

Newron Pharmaceuticals

Pivotal readout moves firmly into view

Newron has announced the completion of screening for its pivotal Phase III ENIGMA-TRS 1 study of evenamide in treatment-resistant schizophrenia (TRS), marking an important milestone. A total of 996 patients have entered screening, with 411 already randomised and 352 still progressing through the 42-day screening assessment. Based on current eligibility rates, Newron expects at least another 200 patients to be randomised, taking the study beyond its protocol target of 600 patients from mid-October. Top-line results from the primary 12-week treatment period are anticipated in Q127, a slight adjustment from prior guidance of Q426. We do not view this modest timing shift as materially changing the investment case. The completion of screening provides increased visibility on delivery of the required study population and brings the first pivotal efficacy readout for evenamide into view. The Q127 readout represents a key potential upcoming catalyst.

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/24	51.4	21.7	0.87	0.00	15.1	N/A
12/25	19.1	(12.1)	(0.65)	0.00	N/A	N/A
12/26e	7.8	(46.4)	(2.23)	0.00	N/A	N/A
12/27e	66.6	32.5	1.19	0.00	11.0	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

According to the [announcement](#), screening for enrolment in ENIGMA-TRS 1 has been completed, providing greater clarity on overall trial timelines. Before randomisation, patients are required to complete 42 days of screening, including confirmation of their treatment-resistant diagnosis, checks of background antipsychotic drug levels and review against protocol criteria by an independent committee of three leaders in the field of schizophrenia. This is intended to ensure that the participants represent a typical TRS population, supporting the interpretability of the pivotal dataset. With 996 patients having entered screening and 411 already randomised, the remaining screening pool appears sufficient to take enrolment above the required 600 participants.

ENIGMA-TRS 1 is a one-year, randomised, double-blind, placebo-controlled trial testing evenamide as an add-on to existing antipsychotics, including clozapine (the only drug approved for TRS, though its use has safety and monitoring limitations). The primary endpoint uses the Positive and Negative Syndrome Scale (PANSS) score at 12 weeks, the gold standard in this indication. The study continues to 26 and 52 weeks, providing evidence on durability, safety and tolerability. Importantly, ENIGMA-TRS 1 has not been affected by the enrolment hold at US sites in the separate [ENIGMA-TRS 2](#) trial, and remains Newron's most imminent inflection point.

Evenamide is designed to modulate excessive glutamate release via selective blockade of voltage-gated sodium channels, providing a novel approach versus available antipsychotics, which mainly act through dopamine pathways. Evenamide enters the pivotal programme with a substantial clinical evidence base. Study 014/015 demonstrated durable and clinically meaningful improvements in patients with TRS, while the international, double-blind, placebo-controlled Phase IIb/III study 008A in 291 poorly responding schizophrenia patients met both its primary and secondary efficacy endpoints with statistical significance. In study 008A, evenamide achieved a significantly greater improvement in PANSS score than placebo at day 29, alongside a tolerability profile similar to placebo. The key question is whether these strong findings can be confirmed in Phase III in the target TRS population.


Clinical trial update

Healthcare

2 September 2026

Price	CHF12.34
Market cap	CHF257m
	€1.06/CHF
Pro forma net cash/(debt) at 31 December 2025	€5.8m
Shares in issue	20.8m
Free float	95.0%
Code	NWRN
Primary exchange	SWX
Secondary exchange	N/A

Share price performance



Business description

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson's disease is sold in Europe, Japan and the United States. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting treatment-resistant schizophrenia.

Analysts

Arron Aatkar, PhD	+44 (0)20 3077 5700
Jyoti Prakash, CFA	+44 (0)20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

**Newron Pharmaceuticals is
a research client of Edison
Investment Research Limited**

General disclaimer and copyright

This report has been commissioned by Newron Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Newron Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
